Related Experiment Videos
Therapeutic use of transfer factor.
European Journal of Clinical Investigation
|February 1, 1975
Summary
Transfer Factor (TF) therapy showed promise in treating chronic candidiasis, with immune conversion and clinical benefits observed in most patients. Further research is needed for other conditions like multiple sclerosis.
Area of Science:
- Immunology
- Cellular Therapy
Background:
- Transfer Factor (TF) is a dialyzable extract from leukocytes with potential immunomodulatory properties.
- Previous studies suggest TF's role in immune modulation, necessitating further clinical investigation.
Purpose of the Study:
- To evaluate the safety and efficacy of Transfer Factor (TF) therapy in patients with various immune-related conditions.
- To assess immune conversion and clinical outcomes in patients receiving TF.
Main Methods:
- TF was produced via ultrafiltration of pooled buffy coats from healthy donors.
- 409 units of TF were administered to 45 patients across different disease categories.
- Patient responses were monitored for immune conversion and clinical effects.
Main Results:
- In chronic candidiasis patients (n=12), 11 showed immune conversion and 10 experienced clinical benefits.
- Immune conversion was noted in multiple sclerosis patients, but clinical effects remain undetermined.
- Limited immune conversion and non-judgemental clinical effects were observed in patients with subacute sclerosing panencephalitis, HBAg-positive disorders, immunodeficiencies, and cancers.
Conclusions:
- TF therapy appears safe, with only minor side effects like local pain and fever reported.
- TF demonstrates potential efficacy in treating chronic candidiasis.
- Further studies are required to ascertain the clinical utility of TF in multiple sclerosis and other complex diseases.